Where does Biogen (BIIB) go from here?
The announcement from the Cambridge, Mass.-based biotech company that it is stopping two clinical trials of its Alzheimer’s drug aducanumab is certainly bad for patients, their families, and for anyone worried about developing this terrible, brain-destroying disease. It’s frustrating for researchers who believed medicines like aducanumab had some hope of slowing an affliction that has stymied all attempts at treating it for a decade and a half.
But there can also be no doubt about this: It’s a big problem for Biogen.
